Valmet (VALMT) AGM 2026 summary

Opening remarks and agenda

• Chairman welcomed shareholders, introduced the Board, and outlined the meeting agenda, emphasizing recent board changes and the importance of board diversity and competence.

• Meeting arrangements, voting procedures, and technical instructions were provided, with simultaneous interpretation available.

Board and executive committee updates

• Board convened 13 times with a 95% attendance rate, focusing on strategy renewal and operating model changes.

• CEO Thomas Hinnerskov, in role for 19 months, was commended for energetic leadership and cultural transformation.

• Two board committees—Audit and People & Remuneration—oversaw sustainability, risk, and incentive plan renewals.

Financial performance review

• Orders received decreased 11% to EUR 5,216 million, mainly due to a tough comparison year in biomaterials.

• Net sales remained steady; comparable EBITDA margin reached a record 11.9%, up 60 basis points from 2024.

• EUR 35 million in cost savings realized from operating model changes, with EUR 80 million expected in total.

• Cash flow was strong at EUR 581 million; balance sheet remains robust, supporting future investments.

• Process Performance Solutions delivered a 19.6% margin, while Biomaterial Solutions and Services maintained 10.3%.